PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Advanced Drug Delivery Reviews

Volumn 99, Issue , 2016, Pages 28-51

  Suk, Jung Soo ^a   Xu, Qingguo ^a   Kim, Namho ^a,b   Hanes, Justin ^a,b,c   Ensign, Laura M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Enhanced permeability and retention (EPR) effect; Liposomes; Mononuclear phagocyte system (MPS); Mucosal delivery; Stealth coatings

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; COATINGS; GENE TRANSFER; GENES; LIPOSOMES;

BIOLOGICAL BARRIER; ENHANCED PERMEABILITY AND RETENTION EFFECTS; MONONUCLEAR PHAGOCYTE SYSTEMS; MUCOSAL DELIVERY; NANOPARTICLE FORMULATION; PEGYLATED NANOPARTICLE; SYSTEMIC ADMINISTRATION; SYSTEMIC CIRCULATION;

NANOPARTICLES;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; CERAMIDE; CHITOSAN; CISPLATIN; CYCLOSPORIN A; DANAZOL; DNA; DOXORUBICIN; GANTREZ COPOLYMER; LIPOPLEX; LIPOSOME; MACROGOL; NANOPARTICLE; PACLITAXEL; PARVOVIRUS VECTOR; PEGADEMASE; PHOSPHATIDYLETHANOLAMINE; POLOXAMER; POLY(2 METHYL 2 OXAZOLINE); POLY(N ACRYLOYL MORPHOLINE); POLY(N,N DIMETHYL ACRYLAMIDE); POLYAMIDOAMINE; POLYCAPROLACTONE; POLYETHYLENEIMINE; POLYGLACTIN; POLYLACTIC ACID; POVIDONE; QUANTUM DOT; UNCLASSIFIED DRUG; UNINDEXED DRUG; MACROGOL DERIVATIVE;

CHEMICAL MODIFICATION; CIRCULATION TIME; DENSITY; DRUG DELIVERY SYSTEM; GENE TARGETING; HUMAN; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; OPSONIZATION; PEGYLATION; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; TARGET CELL; TARGET ORGAN; ANIMAL; CHEMISTRY; GENE TRANSFER; SURFACE PROPERTY;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES; POLYETHYLENE GLYCOLS; SURFACE PROPERTIES;

EID: 84960201366     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.09.012     Document Type: Review

References (245)

1. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
2. Weissig V., Pettinger T.K., Murdock N. Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomedicine 2014, 9:4357-4373.
3. Arturson P., Laakso T., Edman P. Acrylic microspheres in vivo IX: blood elimination kinetics and organ distribution of microparticles with different surface characteristics. J. Pharm. Sci. 1983, 72:1415-1420.
4. Tan J.S., Butterfield D.E., Voycheck C.L., Caldwell K.D., Li J.T. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 1993, 14:823-833.
5. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
6. Ahmed M., Lukyanov A.N., Torchilin V., Tournier H., Schneider A.N., Goldberg S.N. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J. Vasc. Interv. Radiol. 2005, 16:1365-1371.
7. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
8. Laginha K.M., Verwoert S., Charrois G.J., Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res. 2005, 11:6944-6949.
9. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
10. Braet F., Wisse E., Bomans P., Frederik P., Geerts W., Koster A., Soon L., Ringer S. Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions. Microsc. Res. Tech. 2007, 70:230-242.
11. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
12. Vonarbourg A., Passirani C., Saulnier P., Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27:4356-4373.
13. Aderem A., Underhill D.M. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 1999, 17:593-623.
14. Patel H.M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9:39-90.
15. Gessner A., Waicz R., Lieske A., Paulke B., Mader K., Muller R.H. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int. J. Pharm. 2000, 196:245-249.
16. Roser M., Fischer D., Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 1998, 46:255-263.
17. Yoon J.Y., Kim J.H., Kim W.S. Interpretation of protein adsorption phenomena onto functional microspheres. Colloids Surf. B 1998, 12:15-22.
18. Arnida, Janat-Amsbury M.M., Ray A., Peterson C.M., Ghandehari H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur. J. Pharm. Biopharm. 2011, 77:417-423.
19. Liu F., Liu D.X. Serum independent liposome uptake by mouse liver. Bba-Biomembranes 1996, 1278:5-11.
20. Walkey C.D., Olsen J.B., Guo H., Emili A., Chan W.C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 2012, 134:2139-2147.
21. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 2012, 7:779-786.
22. Tenzer S., Docter D., Kuharev J., Musyanovych A., Fetz V., Hecht R., Schlenk F., Fischer D., Kiouptsi K., Reinhardt C., Landfester K., Schild H., Maskos M., Knauer S.K., Stauber R.H. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 2013, 8:772-781.
23. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., Kelly P.M., Aberg C., Mahon E., Dawson K.A. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 2013, 8:137-143.
24. Li S., Rizzo M.A., Bhattacharya S., Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 1998, 5:930-937.
25. Bragonzi A., Boletta A., Biffi A., Muggia A., Sersale G., Cheng S.H., Bordignon C., Assael B.M., Conese M. Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs. Gene Ther. 1999, 6:1995-2004.
26. Liu Y., Mounkes L.C., Liggitt H.D., Brown C.S., Solodin I., Heath T.D., Debs R.J. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 1997, 15:167-173.
27. Yoo J.W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 2010, 16:2298-2307.
28. Yang Q., Lai S.K. Anti-PEG immunity: emergence, characteristics, and unaddressed questions, Wiley interdisciplinary reviews. Nanomed. Nanobiotechnol. 2015, 7:655-677.
29. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
30. Stirland D.L., Nichols J.W., Miura S., Bae Y.H. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J. Control. Release 2013, 172:1045-1064.
31. Kim J., Kim P.H., Kim S.W., Yun C.O. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 2012, 33:1838-1850.
32. Lee G.K., Maheshri N., Kaspar B., Schaffer D.V. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol. Bioeng. 2005, 92:24-34.
33. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
34. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
35. Dawidczyk C.M., Kim C., Park J.H., Russell L.M., Lee K.H., Pomper M.G., Searson P.C. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Release 2014, 187:133-144.
36. von Maltzahn G., Park J.H., Agrawal A., Bandaru N.K., Das S.K., Sailor M.J., Bhatia S.N. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 2009, 69:3892-3900.
37. van der Meel R., Vehmeijer L.J., Kok R.J., Storm G., van Gaal E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 2013, 65:1284-1298.
38. Nance E., Timbie K., Miller G.W., Song J., Louttit C., Klibanov A.L., Shih T.Y., Swaminathan G., Tamargo R.J., Woodworth G.F., Hanes J., Price R.J. Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. J. Control. Release 2014, 189:123-132.
39. Kennedy J.E., Wu F., ter Haar G.R., Gleeson F.V., Phillips R.R., Middleton M.R., Cranston D. High-intensity focused ultrasound for the treatment of liver tumours. Ultrasonics 2004, 42:931-935.
40. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., Blunk T., Muller R.H. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B: Biointerfaces 2000, 18:301-313.
41. Miteva M., Kirkbride K.C., Kilchrist K.V., Werfel T.A., Li H., Nelson C.E., Gupta M.K., Giorgio T.D., Duvall C.L. Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers. Biomaterials 2015, 38:97-107.
42. Mori A., Klibanov A.L., Torchilin V.P., Huang L. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 1991, 284:263-266.
43. Gref R., Domb A., Quellec P., Blunk T., Muller R.H., Verbavatz J.M., Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16:215-233.
44. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
45. Dos Santos N., Allen C., Doppen A.M., Anantha M., Cox K.A., Gallagher R.C., Karlsson G., Edwards K., Kenner G., Samuels L., Webb M.S., Bally M.B. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta 2007, 1768:1367-1377.
46. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
47. Cui J., De Rose R., Alt K., Alcantara S., Paterson B.M., Liang K., Hu M., Richardson J.J., Yan Y., Jeffery C.M., Price R.I., Peter K., Hagemeyer C.E., Donnelly P.S., Kent S.J., Caruso F. Engineering poly(ethylene glycol) particles for improved biodistribution. ACS Nano 2015, 9:1571-1580.
48. He Q., Zhang J., Shi J., Zhu Z., Zhang L., Bu W., Guo L., Chen Y. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials 2010, 31:1085-1092.
49. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009, 9:1909-1915.
50. Mosqueira V.C., Legrand P., Gref R., Heurtault B., Appel M., Barratt G. Interactions between a macrophage cell line (J774A1) and surface-modified poly (D, L-lactide) nanocapsules bearing poly(ethylene glycol). J. Drug Target. 1999, 7:65-78.
51. Mosqueira V.C., Legrand P., Morgat J.L., Vert M., Mysiakine E., Gref R., Devissaguet J.P., Barratt G. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res. 2001, 18:1411-1419.
52. Bazile D., Prudhomme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84:493-498.
53. Fang C., Shi B., Pei Y.Y., Hong M.H., Wu J., Chen H.Z. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 2006, 27:27-36.
54. Yang Q., Jones S.W., Parker C.L., Zamboni W.C., Bear J.E., Lai S.K. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol. Pharm. 2014, 11:1250-1258.
55. Braeckmans K., Buyens K., Bouquet W., Vervaet C., Joye P., De Vos F., Plawinski L., Doeuvre L., Angles-Cano E., Sanders N.N., Demeester J., De Smedt S.C. Sizing nanomatter in biological fluids by fluorescence single particle tracking. Nano Lett. 2010, 10:4435-4442.
56. Zara G.P., Cavalli R., Bargoni A., Fundaro A., Vighetto D., Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target. 2002, 10:327-335.
57. Khalid M.N., Simard P., Hoarau D., Dragomir A., Leroux J.C. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 2006, 23:752-758.
58. Peracchia M.T., Fattal E., Desmaele D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 1999, 60:121-128.
59. DeRouchey J., Walker G.F., Wagner E., Radler J.O. Decorated rods: a "bottom-up" self-assembly of monomolecular DNA complexes. J. Phys. Chem. B 2006, 110:4548-4554.
60. Vittaz M., Bazile D., Spenlehauer G., Verrecchia T., Veillard M., Puisieux F., Labarre D. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 1996, 17:1575-1581.
61. Meng F., Engbers G.H., Feijen J. Polyethylene glycol-grafted polystyrene particles. J. Biomed. Mater. Res. A 2004, 70:49-58.
62. Perry J.L., Reuter K.G., Kai M.P., Herlihy K.P., Jones S.W., Luft J.C., Napier M., Bear J.E., DeSimone J.M. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012, 12:5304-5310.
63. Merkel T.J., Jones S.W., Herlihy K.P., Kersey F.R., Shields A.R., Napier M., Luft J.C., Wu H.L., Zamboni W.C., Wang A.Z., Bear J.E., DeSimone J.M. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:586-591.
64. van Lookeren Campagne M., Wiesmann C., Brown E.J. Macrophage complement receptors and pathogen clearance. Cell. Microbiol. 2007, 9:2095-2102.
65. Unsworth L.D., Sheardown H., Brash J.L. Protein-resistant poly(ethylene oxide)-grafted surfaces: chain density-dependent multiple mechanisms of action. Langmuir 2008, 24:1924-1929.
66. Choi C.H., Zuckerman J.E., Webster P., Davis M.E. Targeting kidney mesangium by nanoparticles of defined size. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6656-6661.
67. Vonarbourg A., Passirani C., Saulnier P., Simard P., Leroux J.C., Benoit J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 2006, 78:620-628.
68. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1482-1487.
69. Jiang X., Qu W., Pan D., Ren Y., Williford J.M., Cui H., Luijten E., Mao H.Q. Plasmid-templated shape control of condensed DNA-block copolymer nanoparticles. Adv. Mater. 2013, 25:227-232.
70. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4930-4934.
71. Shi F., Wasungu L., Nomden A., Stuart M.C., Polushkin E., Engberts J.B., Hoekstra D. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem. J. 2002, 366:333-341.
72. Anselmo A.C., Zhang M., Kumar S., Vogus D.R., Menegatti S., Helgeson M.E., Mitragotri S. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. ACS Nano 2015, 9:3169-3177.
73. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 2008, 5:487-495.
74. Ziemba B., Matuszko G., Bryszewska M., Klajnert B. Influence of dendrimers on red blood cells. Cell. Mol. Biol. Lett. 2012, 17:21-35.
75. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
76. Eliyahu H., Servel N., Domb A.J., Barenholz Y. Lipoplex-induced hemagglutination: potential involvement in intravenous gene delivery. Gene Ther. 2002, 9:850-858.
77. Kurosaki T., Kitahara T., Fumoto S., Nishida K., Yamamoto K., Nakagawa H., Kodama Y., Higuchi N., Nakamura T., Sasaki H. Chondroitin sulfate capsule system for efficient and secure gene delivery. J. Pharm. Pharm. Sci. 2010, 13:351-361.
78. Petersen H., Fechner P.M., Fischer D., Kissel T. Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers. Macromolecules 2002, 35:6867-6874.
79. Qi R., Gao Y., Tang Y., He R.R., Liu T.L., He Y., Sun S., Li B.Y., Li Y.B., Liu G. PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. AAPS J. 2009, 11:395-405.
80. Petersen H., Fechner P.M., Martin A.L., Kunath K., Stolnik S., Roberts C.J., Fischer D., Davies M.C., Kissel T. Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug. Chem. 2002, 13:845-854.
81. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 2010, 49:6288-6308.
82. Verhoef J.J., Carpenter J.F., Anchordoquy T.J., Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov. Today 2014, 19:1945-1952.
83. Abu Lila A.S., Kiwada H., Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 2013, 172:38-47.
84. Mitragotri S., Burke P.A., Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 2014, 13:655-672.
85. Richter A.W., Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 1984, 74:36-39.
86. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105:305-317.
87. Ichihara M., Shimizu T., Imoto A., Hashiguchi Y., Uehara Y., Ishida T., Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2010, 3:1-11.
88. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112:15-25.
89. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., van Der Meer J.W., Corstens F.H., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
90. Mishra S., Webster P., Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 2004, 83:97-111.
91. Shimizu T., Ishida T., Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology 2013, 218:725-732.
92. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 2006, 115:243-250.
93. Ishida T., Kashima S., Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Release 2008, 126:162-165.
94. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 2007, 122:349-355.
95. Saadati R., Dadashzadeh S., Abbasian Z., Soleimanjahi H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm. Res. 2013, 30:985-995.
96. Tagami T., Uehara Y., Moriyoshi N., Ishida T., Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J. Control. Release 2011, 151:149-154.
97. Abu Lila A.S., Eldin N.E., Ichihara M., Ishida T., Kiwada H. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application. Int. J. Pharm. 2012, 438:176-183.
98. Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115:251-258.
99. Tagami T., Nakamura K., Shimizu T., Yamazaki N., Ishida T., Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J. Control. Release 2010, 142:160-166.
100. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005, 23:457-462.
101. Judge A., McClintock K., Phelps J.R., Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 2006, 13:328-337.
102. Tagami T., Nakamura K., Shimizu T., Ishida T., Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J. Control. Release 2009, 137:234-240.
103. Shimizu T., Ichihara M., Yoshioka Y., Ishida T., Nakagawa S., Kiwada H. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol. Pharm. Bull. 2012, 35:1336-1342.
104. Xu H., Ye F., Hu M., Yin P., Zhang W., Li Y., Yu X., Deng Y. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv. 2014, 22:598-607.
105. Shiraishi K., Hamano M., Ma H., Kawano K., Maitani Y., Aoshi T., Ishii K.J., Yokoyama M. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J. Control. Release 2013, 165:183-190.
106. Wang X.Y., Ishida T., Ichihara M., Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J. Control. Release 2005, 104:91-102.
107. Koide H., Asai T., Hatanaka K., Urakami T., Ishii T., Kenjo E., Nishihara M., Yokoyama M., Ishida T., Kiwada H., Oku N. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 2008, 362:197-200.
108. Saifer M.G., Williams L.D., Sobczyk M.A., Michaels S.J., Sherman M.R. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol. Immunol. 2014, 57:236-246.
109. Sherman M.R., Williams L.D., Sobczyk M.A., Michaels S.J., Saifer M.G. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem. 2012, 23:485-499.
110. Ishihara T., Takeda M., Sakamoto H., Kimoto A., Kobayashi C., Takasaki N., Yuki K., Tanaka K., Takenaga M., Igarashi R., Maeda T., Yamakawa N., Okamoto Y., Otsuka M., Ishida T., Kiwada H., Mizushima Y., Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res. 2009, 26:2270-2279.
111. Armstrong J. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). PEGylated Protein Drugs: Basic Science and Clinical Applications, Birkhäuser Basel 2009, 147-168. F. Veronese (Ed.).
112. Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 2012, 9:1319-1323.
113. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 2008, 60:886-898.
114. Kainthan R.K., Brooks D.E. In vivo biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials 2007, 28:4779-4787.
115. Amoozgar Z., Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley interdisciplinary reviews. Nanomed. Nanobiotechnol. 2012, 4:219-233.
116. Abu Lila A.S., Nawata K., Shimizu T., Ishida T., Kiwada H. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int. J. Pharm. 2013, 456:235-242.
117. Abu Lila A.S., Uehara Y., Ishida T., Kiwada H. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery. J. Pharm. Sci. 2014, 103:557-566.
118. Kainthan R.K., Brooks D.E. Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: biodistribution studies. Bioconjug. Chem. 2008, 19:2231-2238.
119. Kierstead P.H., Okochi H., Venditto V.J., Chuong T.C., Kivimae S., Frechet J.M., Szoka F.C. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J. Control. Release 2015, 213:1-9.
120. Anselmo A.C., Gupta V., Zern B.J., Pan D., Zakrewsky M., Muzykantov V., Mitragotri S. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 2013, 7:11129-11137.
121. Rodriguez P.L., Harada T., Christian D.A., Pantano D.A., Tsai R.K., Discher D.E. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339:971-975.
122. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
123. Ensign L.M., Schneider C., Suk J.S., Cone R., Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv. Mater. 2012, 24:3887-3894.
124. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
125. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 2001, 81:1930-1937.
126. Suh J., Dawson M., Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. Adv. Drug Deliv. Rev. 2005, 57:63-78.
127. Huang Y.B., Leobandung W., Foss A., Peppas N.A. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J. Control. Release 2000, 65:63-71.
128. Sahlin J.J., Peppas N.A. Enhanced hydrogel adhesion by polymer interdiffusion: use of linear poly(ethylene glycol) as an adhesion promoter. J. Biomater. Sci. Polym. Ed. 1997, 8:421-436.
129. Serra L., Domenech J., Peppas N.A. Design of poly(ethylene glycol)-tethered copolymers as novel mucoadhesive drug delivery systems. Eur. J. Pharm. Biopharm. 2006, 63:11-18.
130. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. 2008, 47:9726-9729.
131. Cu Y., Saltzman W.M. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm. 2009, 6:173-181.
132. Cu Y., Booth C.J., Saltzman W.M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J. Control. Release 2011, 156:258-264.
133. Yang M., Lai S.K., Wang Y.Y., Zhong W.X., Happe C., Zhang M., Fu J., Hanes J. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. 2011, 50:2597-2600.
134. Ensign L.M., Tang B.C., Wang Y.Y., Tse T.A., Hoen T., Cone R., Hanes J. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 2012, 4. (138ra179).
135. Yang M., Yu T., Wang A.Z., Lai S.K., Zeng Q., Miao B., Tang B.C., Simons B.W., Ensign L., Liu G., Chan K.W.Y., Juang C.-Y., Mert O., Wood J., Fu J., McMahon M.T., Wu T.-C., Hung C.-F., Hanes J. Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv. Healthcare Mater. 2013, 3:1044-1052.
136. Tang B.C., Dawson M., Lai S.K., Wang Y.Y., Suk J.S., Yang M., Zeitlin P., Boyle M.P., Fu J., Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19268-19273.
137. Xu Q., Boylan N.J., Cai S., Miao B., Patel H., Hanes J. Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus. J. Control. Release 2013, 170:279-286.
138. Yu T., Wang Y.Y., Yang M., Schneider C., Zhong W., Pulicare S., Choi W.J., Mert O., Fu J., Lai S.K., Hanes J. Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly(lactic-glycolic acid). Drug Deliv. Transl. Res. 2012, 2.
139. Yu T., Chan K.W., Anonuevo A., Song X., Schuster B.S., Chattopadhyay S., Xu Q., Oskolkov N., Patel H., Ensign L.M., van Zjil P.C., McMahon M.T., Hanes J. Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic resonance imaging (MRI). Nanomed.: Nanotechnol., Biol. Med. 2015, 11:401-405.
140. Xu Q., Ensign L.M., Boylan N.J., Schon A., Gong X., Yang J.-C., Lamb N.W., Cai S., Yu T., Freire E., Hanes J. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 2015, 9:9217-9227.
141. Lai S.K., Wang Y.Y., Wirtz D., Hanes J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 2009, 61:86-100.
142. Wang Y.Y., Lai S.K., So C., Schneider C., Cone R., Hanes J. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One 2011, 6:e21547.
143. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:598-603.
144. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
145. Forier K., Messiaen A.S., Raemdonck K., Deschout H., Rejman J., De Baets F., Nelis H., De Smedt S.C., Demeester J., Coenye T., Braeckmans K. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine (London) 2013, 8:935-949.
146. Konstan M.W., Davis P.B., Wagener J.S., Hilliard K.A., Stern R.C., Milgram L.J., Kowalczyk T.H., Hyatt S.L., Fink T.L., Gedeon C.R., Oette S.M., Payne J.M., Muhammad O., Ziady A.G., Moen R.C., Cooper M.J. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 2004, 15:1255-1269.
147. Boylan N.J., Suk J.S., Lai S.K., Jelinek R., Boyle M.P., Cooper M.J., Hanes J. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. J. Control. Release 2012, 157:72-79.
148. Suk J.S., Boylan N.J., Trehan K., Tang B.C., Schneider C.S., Lin J.M.G., Boyle M.P., Zeitlin P.L., Lai S.K., Cooper M.J., Hanes J. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol. Ther. 2011, 19:1981-1989.
149. Kim A.J., Boylan N.J., Suk J.S., Hwangbo M., Yu T., Schuster B.S., Cebotaru L., Lesniak W.G., Oh J.S., Adstamongkonkul P., Choi A.Y., Kannan R.M., Hanes J. Use of single-site functionalized peg-dendrons to prepare gene vectors that penetrate human mucus barriers. Angew. Chem. Int. Ed. Engl. 2013, 52:3985-3988.
150. Suk J.S., Kim A.J., Trehan K., Schneider C.S., Cebotaru L., Woodward O.M., Boylan N.J., Boyle M.P., Lai S.K., Guggino W.B., Hanes J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J. Control. Release 2014, 178:8-17.
151. Mastorakos P., da Silva A.L., Chisholm J., Song E., Choi W.K., Boyle M.P., Morales M.M., Hanes J., Suk J.S. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:8720-8725.
152. O'Riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., Francis G.E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10:1349-1358.
153. Yang X.Y., Forier K., Steukers L., Van Vlierberghe S., Dubruel P., Braeckmans K., Glorieux S., Nauwynck H.J. Immobilization of pseudorabies virus in porcine tracheal respiratory mucus revealed by single particle tracking. PLoS One 2012, 7.
154. Schuster B.S., Suk J.S., Woodworth G.F., Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013, 34:3439-3446.
155. Lai S.K., Suk J.S., Pace A., Wang Y.Y., Yang M., Mert O., Chen J., Kim J., Hanes J. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials 2011, 32:6285-6290.
156. Brooking J., Davis S.S., Illum L. Transport of nanoparticles across the rat nasal mucosa. J. Drug Target. 2001, 9:267-279.
157. Tobio M., Gref R., Sanchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 1998, 15:270-275.
158. Vila A., Gill H., McCallion O., Alonso M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Release 2004, 98:231-244.
159. Tobio M., Sanchez A., Vila A., Soriano I.I., Evora C., Vila-Jato J.L., Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerfaces 2000, 18:315-323.
160. Feeney O.M., Williams H.D., Pouton C.W., Porter C.J. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. J. Control. Release 2014, 192:219-227.
161. Cheng X., Ming X., Croyle M.A. PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm. Res. 2003, 20:1444-1451.
162. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 2012, 64:557-570.
163. Yuan H., Chen C.Y., Chai G.H., Du Y.Z., Hu F.Q. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol. Pharm. 2013, 10:1865-1873.
164. Inchaurraga L., Martin-Arbella N., Zabaleta V., Quincoces G., Penuelas I., Irache J.M. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration. Eur. J. Pharm. Biopharm. 2014, (in press). 10.1016/j.ejpb.2014.12.021.
165. Maisel K., Ensign L., Reddy M., Cone R., Hanes J. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Release 2015, 197:48-57.
166. Ensign L.M., Henning A., Schneider C.S., Maisel K., Wang Y.Y., Porosoff M.D., Cone R., Hanes J. Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol. Pharm. 2013, 10:2176-2182.
167. Lautenschlager C., Schmidt C., Lehr C.M., Fischer D., Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 2013, 85:578-586.
168. Thorne R.G., Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5567-5572.
169. Nance E.A., Woodworth G.F., Sailor K.A., Shih T.Y., Xu Q., Swaminathan G., Xiang D., Eberhart C., Hanes J. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl. Med. 2012, 4. (149ra119).
170. Nance E., Zhang C., Shih T.Y., Xu Q., Schuster B.S., Hanes J. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano 2014, 8:10655-10664.
171. Mastorakos P., Zhang C., Berry S., Oh Y., Lee S., Eberhart C.G., Woodworth G.F., Suk J.S., Hanes J. Highly PEGylated DNA nanoparticles provide uniform and widespread gene transfer in the brain. Adv. Healthcare Mater. 2015, 4:1023-1033.
172. Mastorakos P., Song E., Zhang C., Berry S., Park H.W., Kim Y.E., Park J.S., Lee S., Suk J.S., Hanes J. Biodegradable DNA nanoparticles that provide widespread gene delivery in the brain 2015, (in press).
173. Jarvinen K., Jarvinen T., Urtti A. Ocular absorption following topical delivery. Adv. Drug Deliv. Rev. 1995, 16:3-19.
174. Giannavola C., Bucolo C., Maltese A., Paolino D., Vandelli M.A., Puglisi G., Lee V.H., Fresta M. Influence of preparation conditions on acyclovir-loaded poly-d, l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm. Res. 2003, 20:584-590.
175. Wang Y.Y., Lai S.K., Suk J.S., Pace A., Cone R., Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew. Chem. Int. Ed. Engl. 2008, 47:9726-9729.
176. Schopf L.R., Popov A.M., Enlow E.M., Bourassa J.L., Ong W.Z., Nowak P., Chen H. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles. Transl. Vis. Sci. Technol. 2015, 4:11.
177. Mun E.A., Morrison P.W., Williams A.C., Khutoryanskiy V.V. On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein. Mol. Pharm. 2014, 11:3556-3564.
178. Sanders N.N., Peeters L., Lentacker I., Demeester J., De Smedt S.C. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J. Control. Release 2007, 122:226-235.
179. Martens T.F., Vercauteren D., Forier K., Deschout H., Remaut K., Paesen R., Ameloot M., Engbersen J.F., Demeester J., De Smedt S.C., Braeckmans K. Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy. Nanomedicine (London) 2013, 8:1955-1968.
180. Xu Q., Boylan N.J., Suk J.S., Wang Y.Y., Nance E.A., Yang J.C., McDonnell P.J., Cone R.A., Duh E.J., Hanes J. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J. Control. Release 2013, 167:76-84.
181. Weaver E.A., Barry M.A. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 2008, 19:1369-1382.
182. van den Berg J.H., Oosterhuis K., Hennink W.E., Storm G., van der Aa L.J., Engbersen J.F., Haanen J.B., Beijnen J.H., Schumacher T.N., Nuijen B. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J. Control. Release 2010, 141:234-240.
183. Qiao Y., Huang Y., Qiu C., Yue X., Deng L., Wan Y., Xing J., Zhang C., Yuan S., Dong A., Xu J. The use of PEGylated poly [2-(N, N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses. Biomaterials 2010, 31:115-123.
184. Zhan X., Tran K.K., Shen H. Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. Mol. Pharm. 2012, 9:3442-3451.
185. Xie Z., Ji Z., Zhang Z., Gong T., Sun X. Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1. Biomaterials 2014, 35:7896-7908.
186. Hatakeyama H., Akita H., Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol. Pharm. Bull. 2013, 36:892-899.
187. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25:55-71.
188. Schneider C.S., Perez J.G., Cheng E., Zhang C., Mastorakos P., Hanes J., Winkles J.A., Woodworth G.F., Kim A.J. Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells. Biomaterials 2015, 42:42-51.
189. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
190. Zuckerman J.E., Gritli I., Tolcher A., Heidel J.D., Lim D., Morgan R., Chmielowski B., Ribas A., Davis M.E., Yen Y. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:11449-11454.
191. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., Low S., McDonnell K., Peeke E., Retnarajan B., Sabnis A., Schnipper E., Song J.J., Song Y.H., Summa J., Tompsett D., Troiano G., Van Geen Hoven T., Wright J., LoRusso P., Kantoff P.W., Bander N.H., Sweeney C., Farokhzad O.C., Langer R., Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012, 4. (128ra139).
192. Pamujula S., Hazari S., Bolden G., Graves R.A., Chinta D.D., Dash S., Kishore V., Mandal T.K. Cellular delivery of PEGylated PLGA nanoparticles. J. Pharm. Pharmacol. 2012, 64:61-67.
193. Hu Y., Xie J., Tong Y.W., Wang C.H. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J. Control. Release 2007, 118:7-17.
194. Chen X., Kube D.M., Cooper M.J., Davis P.B. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol. Ther. 2008, 16:333-342.
195. Suh J., Choy K.L., Lai S.K., Suk J.S., Tang B.C., Prabhu S., Hanes J. PEGylation of nanoparticles improves their cytoplasmic transport. Int. J. Nanomedicine 2007, 2:735-741.
196. Hatakeyama H., Akita H., Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev. 2011, 63:152-160.
197. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., Langer R., Farokhzad O.C. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17939-17944.
198. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2586-2591.
199. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1850-1855.
200. Dhar S., Gu F.X., Langer R., Farokhzad O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17356-17361.
201. Karnik R., Gu F., Basto P., Cannizzaro C., Dean L., Kyei-Manu W., Langer R., Farokhzad O.C. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008, 8:2906-2912.
202. Valencia P.M., Farokhzad O.C., Karnik R., Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat. Nanotechnol. 2012, 7:623-629.
203. Boury F., Ivanova T., Panaiotov I., Proust J.E., Bois A., Richou J. Dynamic properties of poly(DL-lactide) and polyvinyl alcohol monolayers at the air/water and dichloromethane/water interfaces. J. Colloid Interface Sci. 1995, 169:380-392.
204. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., Labrude P., Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release 1998, 50:31-40.
205. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 2002, 82:105-114.
206. Li Y.-P., Pei Y.-Y., Zhang X.-Y., Gu Z.-H., Zhou Z.-H., Yuan W.-F., Zhou J.-J., Zhu J.-H., Gao X.-J. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release 2001, 71:203-211.
207. Park J., Fong P.M., Lu J., Russell K.S., Booth C.J., Saltzman W.M., Fahmy T.M. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed.: Nanotechnol., Biol. Med. 2009, 5:410-418.
208. Khalil N.M., do Nascimento T.C., Casa D.M., Dalmolin L.F., de Mattos A.C., Hoss I., Romano M.A., Mainardes R.M. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B: Biointerfaces 2013, 101:353-360.
209. Esmaeili F., Ghahremani M.H., Esmaeili B., Khoshayand M.R., Atyabi F., Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int. J. Pharm. 2008, 349:249-255.
210. Sheng Y., Yuan Y., Liu C., Tao X., Shan X., Xu F. In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. J. Mater. Sci. Mater. Med. 2009, 20:1881-1891.
211. Yang M., Lai S.K., Yu T., Wang Y.-Y., Happe C., Zhong W., Zhang M., Anonuevo A., Fridley C., Hung A., Fu J., Hanes J. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J. Control. Release 2014, 192:202-208.
212. Torchilin V.P., Weissig V. Liposomes: a Practical Approach 2003, Oxford University Press, Oxford. 2nd ed.
213. Lee S.H., Zhang Z., Feng S.-S. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials 2007, 28:2041-2050.
214. Mert O., Lai S.K., Ensign L., Yang M., Wang Y.-Y., Wood J., Hanes J. A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J. Control. Release 2012, 157:455-460.
215. Mi Y., Liu Y., Feng S.-S. Formulation of Docetaxel by folic acid-conjugated D-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2 k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32:4058-4066.
216. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol (R)). J. Control. Release 2002, 80:129-144.
217. Zhang Z., Feng S.-S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
218. Lin J.-J., Chen J.-S., Huang S.-J., Ko J.-H., Wang Y.-M., Chen T.-L., Wang L.-F. Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications. Biomaterials 2009, 30:5114-5124.
219. Chan J.M., Zhang L., Yuet K.P., Liao G., Rhee J.-W., Langer R., Farokhzad O.C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009, 30:1627-1634.
220. Wang H., Zhao P., Su W., Wang S., Liao Z., Niu R., Chang J. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials 2010, 31:8741-8748.
221. Pulkkinen M., Pikkarainen J., Wirth T., Tarvainen T., Haapa-aho V., Korhonen H., Seppälä J., Järvinen K. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity. Eur. J. Pharm. Biopharm. 2008, 70:66-74.
222. Kim Y., Klutz A.M., Jacobson K.A. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug. Chem. 2008, 19:1660-1672.
223. Sweet D.M., Kolhatkar R.B., Ray A., Swaan P., Ghandehari H. Transepithelial transport of PEGylated Anionic poly(amidoamine) dendrimers: implications for oral drug delivery. J. Control. Release 2009, 138:78.
224. Kim Y., Hechler B., Gao Z.-G., Gachet C., Jacobson K.A. PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. Bioconjug. Chem. 2009, 20:1888-1898.
225. Perrault S.D., Chan W.C.W. Synthesis and surface modification of highly monodispersed, spherical gold nanoparticles of 50-200 nm. J. Am. Chem. Soc. 2009, 131:17042-17043.
226. Uster P.S., Allen T.M., Daniel B.E., Mendez C.J., Newman M.S., Zhu G.Z. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 1996, 386:243-246.
227. Nakamura K., Yamashita K., Itoh Y., Yoshino K., Nozawa S., Kasukawa H. Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods. Biochim. Biophys. Acta Biomembr. 2012, 1818:2801-2807.
228. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
229. Cavalli S., Tipton A.R., Overhand M., Kros A. The chemical modification of liposome surfaces via a copper-mediated [3 + 2] azide-alkyne cycloaddition monitored by a colorimetric assay. Chem. Commun. 2006, 3193-3195.
230. Kumar A., Erasquin U.J., Qin G., Li K., Cai C. "Clickable", polymerized liposomes as a versatile and stable platform for rapid optimization of their peripheral compositions. Chem. Commun. 2010, 46:5746-5748.
231. Sheng Y., Liu C.S., Yuan Y., Tao X.Y., Yang F., Shan X.Q., Zhou H.J., Xu F. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 2009, 30:2340-2348.
232. Wuelfing W.P., Gross S.M., Miles D.T., Murray R.W. Nanometer gold clusters protected by surface-bound monolayers of thiolated poly(ethylene glycol) polymer electrolyte. J. Am. Chem. Soc. 1998, 120:12696-12697.
233. Xia X., Yang M., Wang Y., Zheng Y., Li Q., Chen J., Xia Y. Quantifying the coverage density of poly(ethylene glycol) chains on the surface of gold nanostructures. ACS Nano 2012, 6:512-522.
234. Valencia P.M., Hanewich-Hollatz M.H., Gao W., Karim F., Langer R., Karnik R., Farokhzad O.C. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 2011, 32:6226-6233.
235. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Livaniou E., Evangelatos G., Ithakissios D.S. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm. 2003, 259:115-127.
236. Heald C.R., Stolnik S., Kujawinski K.S., De Matteis C., Garnett M.C., Illum L., Davis S.S., Purkiss S.C., Barlow R.J., Gellert P.R. Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona. Langmuir 2002, 18:3669-3675.
237. Garcia-Fuentes M., Torres D., Martin-Pastor M., Alonso M.J. Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles. Langmuir 2004, 20:8839-8845.
238. Sun C., Du K., Fang C., Bhattarai N., Veiseh O., Kivit F., Stephen Z., Lee D., Ellenbogen R.G., Ratner B., Zhang M. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano 2010, 4:2402-2410.
239. Xu Y., Mehl J.T., Bakhtiar R., Woolf E.J. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal. Chem. 2010, 82:6877-6886.
240. Chuang K.H., Tzou S.C., Cheng T.C., Kao C.H., Tseng W.L., Shiea J., Liao K.W., Wang Y.M., Chang Y.C., Huango B.J., Wu C.J., Chu P.Y., Roffler S.R., Cheng T.L. Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA. Anal. Chem. 2010, 82:2355-2362.
241. Su Y.-C., Chen B.-M., Chuang K.-H., Cheng T.-L., Roffler S.R. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug. Chem. 2010, 21:1264-1270.
242. Cheng T.-L., Cheng C.-M., Chen B.-M., Tsao D.-A., Chuang K.-H., Hsiao S.-W., Lin Y.-H., Roffler S.R. Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug. Chem. 2005, 16:1225-1231.
243. Zabaleta V., Campanero M.A., Irache J.M. An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles. J. Pharm. Biomed. Anal. 2007, 44:1072-1078.
244. Nair L.M., Konkel J., Thomas M., Koberda M. Comparison of electrospray ionization mass spectrometry and evaporative light scattering detections for the determination of Poloxamer 188 in itraconazole injectable formulation. J. Pharm. Biomed. Anal. 2006, 41:725-730.
245. Zillies J.C., Zwiorek K., Winter G., Coester C. Method for quantifying the PEGylation of gelatin nanoparticle drug carrier systems using asymmetrical flow field-flow fractionation and refractive index detection. Anal. Chem. 2007, 79:4574-4580.